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How Reliable Are Serial
Echocardiographic Measurements
in Detecting Regression in Left
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Julius M. Gardin, MD
Orange, California
Left ventricular (LV) mass and geometry determined by
echocardiography have convincingly been shown to predict
cardiovascular morbidity and mortality independent of other
cardiovascular disease (CVD) risk factors (1–7). For exam-
ple, in the Framingham Heart Study, subjects $40 years old
without clinically apparent CVD who were followed for
four years demonstrated a risk factor–adjusted relative risk
of death of 1.5 in men and 2 in women for each 50-g
increment of echocardiographically determined LV mass
adjusted for height (1). In addition, various reports have
suggested that echocardiographic LV mass may be a suitable
measure of subclinical disease, reflecting a stage in the
process beyond, and the accumulated effects of traditional
CVD risk factors (e.g., hypertension, hyperlipidemia, obe-
sity) (8,9). Furthermore, echocardiography has been shown
to be a more sensitive tool than electrocardiography for the
detection of LV hypertrophy (10,11). Although the data are
still sparse, regression of LV hypertrophy, as demonstrated
by echocardiography, appears to be associated with reduced
cardiovascular morbidity (12,13). Consequently, reliable
estimation of LV mass has been an important goal for
researchers and clinicians interested in topics such as CVD
risk stratification, detection of subclinical disease and mea-
surement of potential regression of LV hypertrophy related
to treatments designed to reduce blood pressure and control
obesity (14). In addition, measurements of LV function
(e.g., global LV ejection fraction) have also been shown to
be important indicators of cardiovascular prognosis (15).
See page 1625
Problems of measurement variability and reliability. The
use of serial echocardiographic measurements of LV mass
(e.g., in an attempt to detect the effect of antihypertensive
therapy) has been hampered by problems of measurement
variability and reliability (Table 1) (16–20). For example,
Gottdiener et al. (16) reported on 96 patients with hyper-
tension evaluated with two-dimensionally targeted M-mode
echocardiography twice within 6 6 8 days. Studies were
performed by the same sonographer using the same echo-
cardiography machine and were read by the same echocar-
diogram reader. Despite excellent measurement reliability
(intraclass correlation coefficient [RHO] 5 0.86), the 95%
confidence interval width of a single replicate measurement
of LV mass was 59 g, exceeding the usual decreases in LV
mass observed during antihypertensive treatment. The test–
retest reliability of LV mass measurements was highly
influenced by study quality, which depended importantly on
age and weight. The authors noted that in clinical practice,
or in studies in which factors such as machine, sonographer
and reader are not standardized, the 95% confidence inter-
vals for LV mass measurements might be even greater than
they observed.
Other sources of measurement variability and bias in the
echocardiographic estimation of LV mass have included
those related to interreader and intrareader variability,
intersonographer and intrasonographer performance vari-
ability, biologic variability from beat-to-beat and day-to-day
and missing measurements (unmeasurable LV mass). In the
Coronary Artery Risk Development in Young Adults
(CARDIA) study, measurement variabilities (technical er-
rors) for two-dimensionally directed M-mode LV mass on
the first echocardiographic examination were intrareader
8%, interreader 14%, intrasonographer 10% and inter-
sonographer 10% (21). Similarly, in the Cardiovascular
Health Study, a multicenter study of cardiovascular mor-
bidity and mortality in over 5,000 free-living elderly sub-
jects, the intrareader and interreader measurement variabil-
ities (mean percent difference between measurements) for
LV mass on the first echocardiographic examination were
both 10% (20). In addition, in the Cardiovascular Health
Study, two-dimensionally directed M-mode echocardio-
graphic LV mass could not be adequately measured in
approximately one-third of the subjects (20,22). Factors
associated with missing LV mass measurements included
obesity, diabetes, male gender, white race, history of myo-
cardial infarction and presence of echocardiographic LV
wall motion abnormalities. Clearly, the association of miss-
ing LV mass measurements with known CVD or CVD risk
factors introduced selection bias as an issue, because patients
in whom LV mass could be measured represented a lower
risk subgroup of the entire cohort. One strategy adopted to
overcome this bias was the development of an electrocar-
diographic model for LV mass estimation based on a
comparison of the two-thirds of the Cardiovascular Health
Study subjects in whom LV mass estimates could be derived
from echocardiography as well as electrocardiography (23).
Another important source of variability in serial studies is
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the potential for change in the exact method by which
readers make measurements over time. For example, in the
CARDIA study, the variability in measurements of LV
mass made on the same studies measured five years apart by
a single reader was in the range of 16%, as compared with
the ;4% intrareader variability for LV mass measurements
made on studies reread by the same reader within a few
weeks of each other during the initial year. This temporal
drift in measurements resulted in redesigning the protocol
to reread the initial studies in temporal proximity to the
follow-up studies recorded five years later (Gardin JM,
unpublished data).
Important findings of the current study. In this issue of
JACC, Palmieri et al. (24) report data on intrapatient
reliability of LV mass measurements in 183 hypertensive
subjects, all of whom were judged to have LV hypertrophy
on their screening echocardiograms, from the Prospective
Randomized Enalapril Study Evaluating Regression of
Ventricular Enlargement (PRESERVE). A second echo-
cardiogram was repeated at the time of randomization
(45 6 25 days later). Analyses of intrapatient reliability were
reported for comparisons of measurements of LV mass,
internal dimension and wall thickness, systolic function and
diastolic filling. A strength of this report is that in addition
to presenting data on intrapatient differences noted between
two readings, the authors present comparison data, at least
for LV mass, between the observed measurement difference
and the expected difference based on a formula used to
predict “regression to the mean,” a statistical artifact that
may confound attempts to detect serial measurement
changes (25,26). Specifically, as the authors note, this
regression phenomenon typically occurs in selected subjects
(e.g., patients with LV hypertrophy) who have a variable
(i.e., LV mass) that exceeds a specified partition value.
Because of regression to the mean, repeat studies in the
selected group of patients (with high values for LV mass)
may reveal a lower mean value of LV mass on the second
study simply because of random fluctuation of measure-
ments. Parenthetically, regression to the mean may also be
operative when one chooses patients with the lowest values
in the group. The magnitude of regression to the mean
(R[g], in grams) likely to affect the “change” in LV mass
measurement over time can be estimated by the formula
(25,26): R(g) 5 (H 2 N) 3 (1 2 r), where H is the average
value of LV mass in a patient group selected for high
baseline values of LV mass; N is the center of distribution of
LV mass within a reference group; and r is the interindi-
vidual variability/total variability for the LV measurement.
Using a calculated reference value of 170 g for LV mass
based on the report of Hammond et al. (27), as well as a
ratio r of 0.70, Palmieri et al. (24) derive, as did Herpin and
Demange (26), a simplified formula for predicting LV mass
on the second (randomization) study from the following
formula: Rg(%) 5 3910/LVMg 2 23, where Rg(%) is the
percent reduction expected for absolute LV mass at the
second evaluation (based on regression to the mean) and
LVMg is LV mass measured on the initial study (in grams).
Of interest, in the Palmieri report, mean average LV mass
decreased less between the first and second echocardiograms
than would be expected from the above “regression to the
mean” formula (2 6 19 vs. 17 6 12 g, p , 0.001). One
factor that may have contributed to this relatively small
difference was the small increase in blood pressure noted
between the first and second echocardiograms, which may
have resulted in some increase in LV mass, thereby blunting
the expected regression to the mean. However, this con-
founding situation, if present, no doubt had a minor effect
on the measurement difference. As emphasized by Palmieri
et al. (24) and other investigators (28), the higher the
reliability of the measurements, the less regression to the
mean would be expected. In this regard, the authors employ
careful methodology, including strategies described later, to
decrease echocardiographic measurement variability. The
excellent intrastudy reliability is reflected in high RHO for
LV mass (0.93), LV internal diameter (0.87), ventricular
septal thickness (0.85) and LV posterior wall thickness
(0.83). In addition, substantial or moderate reliability was
observed for measures of LV systolic function and diastolic
filling, with RHO ranging from 0.71 to 0.57.
Specific measures used by the authors to decrease mea-
surement variability included centralized reading of all
studies with a single, highly experienced final arbiter of
readings, use of a standardized echocardiographic protocol
and a “hands-on” training program for sonographers (29).
In addition, the authors substituted linear measurements of
LV wall thickness and internal dimension from the two-
dimensional parasternal long-axis view whenever the two-
dimensionally directed M-mode beam was not ideally ori-
ented for deriving thickness and dimension measurements.
Because of the relatively older ages (all were at least 50 years
old) and body mass indexes of the study participants, the
majority of measurements in the study were made directly
from the two-dimensional echocardiographic views. This
strategy was no doubt useful in avoiding the selection bias
related to missing LV mass measurements in elderly subjects
at higher risk for CVD noted in the Cardiovascular Health
Study (22). In addition, the design of the current study, in
which both screening and randomization echocardiograms
were recorded within a relatively short period (45 6 25
Table 1. Echocardiographic Estimation of Left Ventricular






6. Biologic (day-to-day) variability
7. Reader (temporal) drift
8. Regression to the mean
9. Left ventricular mass unmeasurable (missing)
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days), provided the possibility of averaging two sets of
measurements of LV mass and function at baseline, which
would tend to minimize the influence of factors contribut-
ing to measurement variability and regression to the mean.
One minor limitation of the current study is that the
contribution of intrareader and intrasonographer variability
could not be measured because they were subsumed in the
overall measurement of intrapatient variability between the
screening and randomization echocardiographic studies.
Furthermore, the current report does not deal with inter-
reader and intersonographer variability, beat-to-beat vari-
ability, temporal drift or bias related to missing measure-
ments (Tables 1 and 2).
Strategies for minimizing measurement variability.
Strategies that have been proposed for minimizing measure-
ment variability in echocardiographic studies involving mea-
surement of LV mass, including serial studies designed to
detect changes (regression) in LV mass, include those
summarized in Table 2 (20,22,24,30).
In addition, other echocardiographic techniques (e.g.,
two-dimensional [31] or three-dimensional [32]) can be
used to estimate LV mass. Some workers have reported LV
measurements calculated from two-dimensional echocar-
diographic slice areas and thicknesses to be superior to
calculations performed from two-dimensionally directed
M-mode echocardiography (31). However, not all investi-
gators agree on the superiority of two-dimensional echocar-
diographic estimates of LV mass. Further improvements
over standard two-dimensional echocardiographic estimates
of LV mass have been reported using three-dimensional
localization of image slices (32) and real-time three-
dimensional echocardiographic image acquisition (33). Su-
perior accuracy for LV mass determination by magnetic
resonance imaging has been reported in an in vivo canine
study, with equivalent accuracy using end-diastolic (r 5
0.94, SEE 5 9 g) or end-systolic (r 5 0.97, SEE 5 7 g)
frames (34). In comparison, in an early necropsy comparison
study, the standard error of two-dimensionally derived
M-mode echocardiographic measurements for estimating
LV mass was $30 g (35).
In summary, this study by Palmieri et al. (24) adds
significantly to our understanding of the optimal methods
for achieving the excellent measurement reliability necessary
for application of echocardiographic measurements to de-
tecting regression in LV mass after appropriate treatment
(for hypertension, obesity, etc.). This rigorous approach to
improving reliability of measurements is critical if echocar-
diography is to be used to document serial changes in LV
mass in the face of excellent alternative—although currently
more cumbersome and expensive, noninvasive imaging
technologies such as magnetic resonance imaging and com-
puted tomography.
Reprint requests and correspondence: Dr. Julius M. Gardin,
Division of Cardiology, University of California Irvine Medical
Center, Rt. 81, 101 City Drive South, Building 53, Room 100,
Orange, California 92868-4080.
REFERENCES
1. Levy D, Garrison RT, Savage DD, et al. Prognostic implications of
echocardiographically determined left ventricular mass in the Fra-
mingham Heart Study. N Engl J Med 1990;332:1561–6.
2. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular
mass and geometry to morbidity and mortality in uncomplicated
essential hypertension. Ann Intern Med 1991;114:345–52.
3. Mensah GA, Koren MJ, Ullin R, et al. Comparison of classification of
the severity of hypertension of blood pressure level and by World
Health Organization criteria in the prediction of concurrent cardiac
abnormalities and subsequent complication in essential hypertension.
J Hypertens 1993;11:1429–40.
Table 2. Potential Quality Control Methods to Decrease Echocardiographic (Left Ventricular Mass) Measurement Variability
1. Standardized “hands-on” training of echocardiographic sonographers and readers
2. On-site observation of experienced sonographers by trained physician echocardiographers
3. Strategies to optimize image quality, including using latest generation echocardiographic equipment and recording images
digitally, if possible
4. Centralized reading, ideally with a highly experienced single adjudicator, or limited number of final adjudicators; minimize
number of sonographers and readers
5. Blind duplicate readings for documenting intrareader and interreader and sonographer variability during the pilot phase and
throughout the study
6. Periodic reader review sessions and adjudication of duplicate studies in which measurement variability exceeds a predetermined
standard
7. Perform measurements of left ventricular wall thickness and internal dimensions from two-dimensional long axis view when two-
dimensionally derived M-mode measurements are not possible or are unreliable
8. Average measurements from multiple beats
9. Average measurements from two or more readings of the same study and/or two or more studies performed at approximately the
same time
10. Reread initial studies at the same time as follow-up studies to minimize temporal drift
11. Calibrate echocardiography machines and reading stations periodically using the appropriate phantoms/calibration tools
12. If there are an excessive number of missing measurements, use different techniques to estimate LV mass (e.g.,
echocardiographically derived electrocardiographic algorithm, three-dimensional echocardiography or magnetic resonance imaging)
1635JACC Vol. 34, No. 5, 1999 Gardin
November 1, 1999:1633–6 Editorial Comment
4. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood
pressure: an independent predictor of prognosis in arterial hyperten-
sion. Hypertension 1994;24:793–801.
5. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and the risk
of stroke in an elderly cohort: the Framingham Heart Study. JAMA
1994;272:33–6.
6. Liao Y, Cooper RS, McGee DL, et al. The relative effects of left
ventricular hypertrophy, coronary artery disease, and ventricular dys-
function on survival among black adults. JAMA 1995;273:1592–7.
7. Gottdiener JS, Shemanski L, Gardin JM, Aurigemma G, Kitzman
DW. Echocardiographic predictors of incident congestive heart failure
in elderly without prevalent cardiovascular disease: the Cardiovascular
Health Study (abst). Circulation 1996;94 Suppl I:I-691.
8. Devereux RB, Alderman MH. Role of preclinical cardiovascular
disease in the evolution from risk factor exposure to development of
morbid events. Circulation 1993;88:1444–55.
9. Kuller L, Shemanski L, Psaty B, et al. Subclinical disease as an
independent risk factor for cardiovascular disease: the Cardiovascular
Health Study. Circulation 1995;92:720–6.
10. Levy D, Labib SB, Anderson KM, et al. Determinants of sensitivity
and specificity of electrocardiographic criteria for left ventricular
hypertrophy. Circulation 1990;81:815–20.
11. Woythaler JN, Singer SL, Kwan OL, et al. Accuracy of echocardiog-
raphy versus electrocardiography in detecting left ventricular hypertro-
phy: comparison with postmortem mass measurements. J Am Coll
Cardiol 1983;2:305–11.
12. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of
serial changes in left ventricular mass in essential hypertension.
Circulation 1998;97:48–54.
13. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L,
Haynemann G. Management of essential hypertension in patients
with different degrees of left ventricular hypertrophy: multicenter trial.
Am J Hypertens 1992;5(Pt. 2):182S–189S.
14. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five
antihypertensive monotherapies and placebo for change in left ventric-
ular mass in patients receiving nutritional-hygienic therapy in the
Treatment of Mild Hypertension Study (TOMHS). Circulation
1995;91:698–706.
15. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated
patients in the Coronary Artery Surgery Study (CASS) Registry.
Circulation 1982;66:562–8.
16. Gottdiener JS, Livengood SV, Meyer PS, Chase GA. Should echo-
cardiography be performed to assess effects of antihypertensive ther-
apy? Test–retest reliability of echocardiography for measurement of
left ventricular mass and function. J Am Coll Cardiol 1995;25:424–30.
17. Wallerson DC, Devereux RB. Reproducibility of echocardiographic
left ventricular measurements. Hypertension 1987;9:II6–18.
18. Devereux RB, Dahlof B. Criteria for an informative trial of left
ventricular hypertrophy regression. J Hum Hypertens 1994;8:735–9.
19. de Simone G, Ganau A, Verdecchia P, Devereux RB. Echocardiog-
raphy in arterial hypertension: when, why and how? J Hypertens
1994;12:1129–36.
20. Gardin JM, Wong ND, Bommer W, et al. Echocardiographic design
of a multi-center investigation of free-living elderly subjects: the
Cardiovascular Health Study. J Am Soc Echocardiogr 1992;5:63–72.
21. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE.
Prevalence of hypertrophic cardiomyopathy in a general population of
young adults: echocardiographic analysis of 4,111 subjects in the
CARDIA study. Circulation 1995;92:785–9.
22. Gardin JM, Siscovick D, Anton-Culver H, et al. Sex, age, and disease
affect echocardiographic left ventricular mass and systolic function in
the free-living elderly: the Cardiovascular Health Study. Circulation
1995;91:1739–48.
23. Rautaharju PM, Manolio TA, Siscovick D, et al. Utility of new
electrocardiographic models for left ventricular mass in older adults.
Hypertension 1996;28:8–15.
24. Palmieri V, Dahlof B, DeQuattro V, et al. Reliability of echocardio-
graphic assessment of left ventricular structure and function: the
PRESERVE study. J Am Coll Cardiol 1999;34:1625–32.
25. Davis CE. The effect of regression to the mean in epidemiologic and
clinical studies. Am J Epidemiol 1976;104:493–8.
26. Herpin D, Demange J. Effect of regression to the mean in serial
echocardiographic measurements of left ventricular mass: quantifica-
tion and clinical implication. Am J Hypertens 1994;7:824–8.
27. Hammond IW, Devereux RB, Alderman MH, et al. The prevalence
and correlates of echocardiographic left ventricular hypertrophy among
employed patients with uncomplicated hypertension. J Am Coll
Cardiol 1986;7:639–50.
28. Fleiss JL. The Design and Analysis of Clinical Experiments. New
York: Wiley, 1986:5–12.
29. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of
enalapril versus nifedipine to decrease left ventricular hypertrophy in
systemic hypertension (the PRESERVE trial). Am J Cardiol 1996;78:
61–5.
30. Gardin JM, Wagenknecht LE, Anton-Culver H, et al. Relationship of
cardiovascular risk factors to echocardiographic left ventricular mass in
healthy young black and white adult men and women: the CARDIA
study. Circulation 1995;92:380–7.
31. Collins HW, Kronenberg MW, Byrd BF. Reproducibility of left
ventricular mass measurements by two-dimensional and M-mode
echocardiography. J Am Coll Cardiol 1989;14:672–6.
32. Gopal AS, Schnellbaecher MJ, Shen Z, Boxt LM, Katz J, King DL.
Freehand three-dimensional echocardiography for determination of
left ventricular volume and mass in patients with abnormal ventricles:
comparison with magnetic resonance imaging. J Am Soc Echocardiogr
1997;10:853–61.
33. Schmidt MA, Laurienzo JM, Brenneman CL, et al. Accuracy of left
ventricular ventricular mass measurements using real-time three-
dimensional echocardiography (abstr). Circulation 1998;17 Suppl
I:I-153.
34. Shapiro EP, Rogers WJ, Beyar R, et al. Determination of left
ventricular mass by magnetic resonance imaging in hearts deformed by
acute infarction. Circulation 1989;79:706–11.
35. Devereux R, Reichek N. Echocardiographic determination of left
ventricular mass in man: anatomic validation of the method. Circula-
tion 1977;55:613–8.
1636 Gardin JACC Vol. 34, No. 5, 1999
Editorial Comment November 1, 1999:1633–6
